Document Detail

beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
MedLine Citation:
PMID:  19351774     Owner:  NLM     Status:  MEDLINE    
PURPOSE: beta-catenin is the downstream effector of the Wnt signaling pathway, and it regulates cell proliferation. beta-catenin overexpression correlates positively with prognosis in several types of malignancies. We herein assessed its effects on growth of multiple myeloma cells using a xenograft model. EXPERIMENTAL DESIGN: We first investigated the expression of beta-catenin in multiple myeloma cell lines and multiple myeloma cells obtained from patients. Next, we investigated the growth inhibitory effects of beta-catenin small interfering RNA on the growth of multiple myeloma cells in vivo. Six-week-old male BALB/c nu/nu mice were inoculated s.c. in the right flank with 5 x 10(6) RPMI8226 cells, followed by s.c. injections of beta-catenin small interfering RNA, scramble small interfering RNA, or PBS/atelocollagen complex twice a week for a total of eight injections. RESULTS: Significantly higher levels of beta-catenin expression were observed in multiple myeloma cell lines and in samples from patients with multiple myeloma than those found in mononuclear cells obtained from healthy volunteers. In in vivo experiments, no inhibitory effects were observed following treatment with scramble small interfering RNA or PBS/atelocollagen complexes, whereas treatment with beta-catenin small interfering RNA/atelocollagen complex significantly inhibited growth of multiple myeloma tumors (P < 0.05). CONCLUSIONS: beta-catenin small interfering RNA treatment inhibited the growth of multiple myeloma tumors in a xenograft model. To our knowledge, this is the first report showing that the treatment with beta-catenin small interfering RNA produces an inhibitory effects on growth of hematologic malignancies in vivo. Because treatment with beta-catenin small interfering RNA inhibited growth of multiple myeloma cells, beta-catenin is the attractive novel target for treating multiple myeloma.
Eishi Ashihara; Eri Kawata; Yoko Nakagawa; Chihiro Shimazaski; Junya Kuroda; Kyoko Taniguchi; Hitoji Uchiyama; Ruriko Tanaka; Asumi Yokota; Miki Takeuchi; Yuri Kamitsuji; Tohru Inaba; Masafumi Taniwaki; Shinya Kimura; Taira Maekawa
Related Documents :
8416744 - Immunoelectron microscopic localization of transforming growth factor beta 1 and latent...
18262174 - Glycosylation of dodecyl 2-acetamido-2-deoxy-beta-d-glucopyranoside and dodecyl beta-d-...
20080554 - Suppression of alk8-mediated bmp signaling cell-autonomously induces pancreatic beta-ce...
8898374 - Aspirin-triggered lipoxins (15-epi-lx) are generated by the human lung adenocarcinoma c...
4027624 - 28 k cholecalcin (cabp) levels in abnormal cerebella: studies on mutant mice and harmal...
8678974 - Enzymatic properties of transplanted glomerulosa cells.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-04-07
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  15     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-16     Completed Date:  2009-06-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2731-8     Citation Subset:  IM    
Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto University Hospital, Kyoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Line, Tumor
Cell Proliferation
Gene Knockdown Techniques
Mice, Inbred BALB C
Mice, Nude
Multiple Myeloma / metabolism*,  pathology
RNA, Small Interfering / genetics*
Transplantation, Heterologous / pathology
beta Catenin / antagonists & inhibitors*,  genetics
Reg. No./Substance:
0/RNA, Small Interfering; 0/beta Catenin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in...
Next Document:  CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer t...